Advertisement

We need your help now

Support from readers like you keeps The Journal open.

You are visiting us because we have something you value. Independent, unbiased news that tells the truth. Advertising revenue goes some way to support our mission, but this year it has not been enough.

If you've seen value in our reporting, please contribute what you can, so we can continue to produce accurate and meaningful journalism. For everyone who needs it.

File photo of an asthma sufferer using an inhaler. Clive Gee/PA

TCD research could lead to new treatment for asthma, dermatitis

Study has found new cells which contribute to the exacerbation of allergic diseases.

RESEARCH WORK carried out in collaboration by scientists at Trinity College in Dublin and at Cambridge, England has the potential to be used in new methods of treating asthma, atopic dermatitis and other allergic diseases.

The research published in Nature Immunology identified new processes which lead to the development of a novel cell which contribute to allergies. The report’s authors say that they discovered distinct and previously-unknown nuocytes (which contribute to the exacerbation of asthma) arising in bone marrow.

The work was performed by Prof Padraig Fallon, Science Foundation Ireland Stokes Professor of Translational Immunology at TCD, and Dr Andrew McKenzie of the Medical Research Council Laboratory for Molecular Biology in Cambridge.

The researchers say that their findings identify targets for allergic diseases which could be developed into treatments.

Readers like you are keeping these stories free for everyone...
A mix of advertising and supporting contributions helps keep paywalls away from valuable information like this article. Over 5,000 readers like you have already stepped up and support us with a monthly payment or a once-off donation.

Close
8 Comments
    Submit a report
    Please help us understand how this comment violates our community guidelines.
    Thank you for the feedback
    Your feedback has been sent to our team for review.
    JournalTv
    News in 60 seconds